Monday, August 31, 2020 5:48:27 PM
Can you provide an equally clear explanation for why a DECN product described by CEO Berman as having been "validated at the company's R&D center in Daegu, Korea for the H5N1 virus and most recently the methodologically similar corona virus" on March 18th of this year hasn't been validated adequately in the US to receive an Emergency Use Authorization?
Why haven't the test results that "validated" GenViro!™ in Korea been shared publicly?
You didn't hesitate to defend the insurability of the diabetic product....please don't hide under the "call the Company" skirt for Covid-19 diagnostic kits. The CEO must have shared his reasoning with you.
I'm not questioning the truth of what the Company is saying. I just don't understand it. Quit whining and explain it.
FEATURED Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • Apr 25, 2024 8:52 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM